The ED Treatment Pipeline: 7 Breakthroughs Coming by 2028

PDE5 inhibitors have dominated ED treatment for nearly three decades. They work, they're affordable, and they've helped tens of millions of men. But they're also a one-mechanism solution to a multi-mechanism problem — and for the 15–30% of men who don't respond adequately, the options have been limited.

That's changing. The ED treatment pipeline in 2026 is the most active it's been since sildenafil's approval, with novel mechanisms, new delivery methods, and regenerative approaches moving through clinical trials. Here are seven developments worth watching.

1. Next-Generation Melanocortin Agonists

PT-141 (bremelanotide) proved that targeting the brain's desire pathways works for sexual dysfunction. But it has limitations — primarily nausea and the need for injection or sublingual dosing. Several pharmaceutical companies are developing next-generation melanocortin-4 receptor agonists designed for better tolerability and oral bioavailability.

These compounds aim to activate MC4R more selectively, reducing the GI side effects that limit PT-141's appeal. If successful, they would provide an oral pill that enhances sexual desire and arousal through central nervous system pathways — something no currently available medication does effectively in pill form.

Timeline: Phase 2 data expected by 2027 for lead candidates.

2. On-Demand Nasal Spray Formulations

Intranasal delivery of ED medications offers a compelling advantage: absorption through the nasal mucosa is fast (onset in 5–15 minutes), bypasses first-pass liver metabolism, and doesn't require an empty stomach. Several companies are developing nasal spray formulations of existing PDE5 inhibitors.

The most advanced programs combine a PDE5 inhibitor with a permeation enhancer that allows rapid absorption through the nasal epithelium. Early clinical data shows onset of action approximately 3–4 times faster than oral tablets, with comparable peak effect and duration.

For men whose primary complaint is that oral tablets take too long to work or require meal-timing planning, a nasal spray could be transformative. It also opens ED treatment to men who have difficulty with oral absorption due to GI conditions or bariatric surgery.

Timeline: Phase 3 trials underway, potential FDA submissions by late 2027.

3. Topical PDE5 Inhibitors

Applying ED medication directly to the penis — as a cream, gel, or spray — would deliver the drug exactly where it's needed while minimizing systemic side effects like headache, flushing, and blood pressure changes. The challenge has always been penetration: penile skin doesn't absorb most molecules well enough to achieve therapeutic concentrations in the underlying erectile tissue.

New formulation technologies using permeation enhancers and nanoparticle delivery systems are making topical delivery viable. One topical sildenafil product has already gained regulatory approval in some markets outside the US, and several are in late-stage US development.

The appeal is obvious: targeted delivery, fewer systemic side effects, rapid onset, and no drug interactions with nitrates (the topical dose is a fraction of the oral dose). For men who can't take oral PDE5 inhibitors due to cardiovascular medications, topical formulations could reopen treatment options that were previously off the table.

Timeline: US regulatory submissions expected 2027–2028.

4. Low-Intensity Shockwave Therapy (Li-ESWT)

This isn't new — shockwave therapy for ED has been offered by clinics for years. What's new is the quality of evidence. Recent multicenter randomized controlled trials have produced more rigorous data than the earlier small studies, and the results are encouraging for a specific patient population: men with mild to moderate vascular ED.

The mechanism involves applying focused acoustic waves to penile tissue, stimulating neovascularization (new blood vessel growth) and neurogenesis. The treatment is non-invasive, performed in a series of office visits over several weeks, with effects that may last 1–2 years.

Li-ESWT is not a replacement for PDE5 inhibitors in most men, but it may restore sufficient natural function that some men can reduce or eliminate medication use. It's particularly interesting for men who want to address the underlying vascular cause rather than manage the symptom.

Timeline: Improved treatment protocols and larger trial data expected through 2027, with potential FDA device clearance updates.

5. Gene Therapy Approaches

Gene therapy for ED remains in early-stage research, but the concept is compelling. The approach involves delivering genes that encode for proteins involved in smooth muscle relaxation or nitric oxide synthesis directly to penile tissue, potentially producing a long-lasting or permanent improvement in erectile function.

Animal studies have demonstrated proof of concept: injecting genes for endothelial nitric oxide synthase (eNOS) or potassium channel proteins into erectile tissue improved function in rodent models of ED. The translation to human applications faces significant technical and safety hurdles, but several academic research programs are actively working toward early-phase human trials.

If successful, gene therapy could theoretically provide a single-treatment cure for vascular ED — eliminating the need for ongoing medication entirely. That's the most ambitious goal in the ED treatment field.

Timeline: Early human trials potentially beginning 2027–2028. Widespread availability, if it works, is likely a decade away.

6. Stem Cell and PRP Therapies

Regenerative approaches using stem cells (typically mesenchymal stem cells) or platelet-rich plasma (PRP) injected into erectile tissue are being studied for their potential to repair damaged smooth muscle, nerves, and blood vessels. Unlike PDE5 inhibitors, which manage the symptom, regenerative therapies aim to restore the tissue's native function.

Clinical trial data is still limited but growing. A 2025 systematic review found that stem cell therapy for ED showed promising results in small trials, particularly for men with post-prostatectomy ED and diabetes-related ED — two populations where conventional treatment often falls short. PRP data is more mixed, with some studies showing benefit and others showing no significant difference from placebo.

The field needs larger, longer-term randomized controlled trials before these approaches can be recommended as standard treatment. But for men with treatment-resistant ED, they represent a genuine frontier of possibility.

Timeline: Larger randomized controlled trials reporting through 2027–2028.

7. Soluble Guanylate Cyclase (sGC) Stimulators

While PDE5 inhibitors prevent the breakdown of cyclic GMP (the downstream molecule that relaxes smooth muscle), sGC stimulators work upstream — directly activating the enzyme that produces cGMP in the first place. This is a fundamentally different and potentially more potent approach to the same pathway.

sGC stimulators are already approved for pulmonary hypertension (riociguat/Adempas), proving the mechanism works in human vascular tissue. Adapting this approach for ED is an active area of pharmaceutical research, with the potential to help men who don't respond to PDE5 inhibitors because their issue is upstream in the nitric oxide-cGMP signaling cascade.

Timeline: Phase 2 trials in ED populations expected by 2027.

Explore ED Treatment Providers

Vetted telehealth platforms offering prescription ED treatments. All links are affiliate partnerships.